Calidi Biotherapeutics (CLDI) Stock: Buy, Sell, or Hold?
CLDI - Calidi Biotherapeutics, Inc.
$1.24
-0.07 (-5.34%)
▼
5d:
-8.15%
30d:
-23.93%
90d:
+632.43%
HOLD
MODERATE Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 14, 2026
0d
Get Alerted When CLDI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CLDI shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CLDI shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CLDI is currently trading at $1.24, which is considered oversold relative to its 30-day fair value range of $1.27 to $1.58.
Technical Outlook: Technically, CLDI is in a strong uptrend. The price is currently testing key support at $1.22. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.3% recently.
Market Sentiment: The stock scores a mixed 59/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $120.00 (+9577.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CLDI is in a strong uptrend. The price is currently testing key support at $1.22. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.3% recently.
Market Sentiment: The stock scores a mixed 59/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $120.00 (+9577.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.27 -
$1.58
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (59/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.3%)
- BULLISH: Trading 9577.8% below Wall St target ($120.00)
- NEUTRAL: Bottoming setup forming (59/100) — watch for confirmation
- CAUTION: 5-day price weakness (-8.1%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$1.27 -
$1.58
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.22
Resistance Level
$1.41
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.22
Wall Street Target
$120.00
(+9577.8%)
Share & Embed Analysis
Last updated: September 13, 2026 11:17 AM ET
Data refreshes hourly during market hours. Next update: 12:17 PM
Data refreshes hourly during market hours. Next update: 12:17 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLDI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 32 SELL |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$849 | 50 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$290 | 59 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 39 SELL |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 41 HOLD |
